Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
477.89
+3.62 (0.76%)
At close: Mar 4, 2026, 4:00 PM EST
477.00
-0.89 (-0.19%)
After-hours: Mar 4, 2026, 4:10 PM EST
| Period Ending | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 7.29B | 7.03B | 6.82B | 6.68B | 6.42B | 6.26B | 6.16B | 6.04B | ||||||||||||||||
| United States Growth | 13.58% | 12.27% | 10.75% | 10.67% | 8.37% | 7.47% | 7.35% | 5.98% | ||||||||||||||||
| Europe | 3.41B | 3.42B | 3.31B | 3.45B | 3.36B | 3.28B | 3.27B | 3.11B | ||||||||||||||||
| Europe Growth | 1.47% | 4.31% | 1.34% | 11.09% | 9.68% | 8.30% | 13.50% | 14.91% | ||||||||||||||||
| Other | 991.70M | 939.20M | 958.10M | 881.30M | 846.30M | 798.40M | 759.30M | 719.80M | ||||||||||||||||
| Other Growth | 17.18% | 17.64% | 26.18% | 22.44% | 26.86% | 22.36% | 28.11% | 36.87% |
Revenue By Segment
| Period Ending | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Trikafta and Kaftrio | 10.31B | 10.46B | 10.39B | 10.29B | 10.19B | 9.81B | 9.50B | 9.29B | - | - | - | ||||||||||||||
| Trikafta and Kaftrio Growth | 1.18% | 6.67% | 9.44% | 10.80% | 13.95% | 13.59% | 13.46% | 15.77% | - | - | - | ||||||||||||||
| Kalydeco | - | - | - | - | - | - | - | - | 475.50M | 499.20M | 525.80M | 539.20M | 553.20M | 569.30M | 592.30M | 636.90M | |||||||||
| Kalydeco Growth | - | - | - | - | - | - | - | - | -14.05% | -12.31% | -11.23% | -15.34% | -19.15% | -21.52% | -21.74% | -17.99% | |||||||||
| Orkambi | - | - | - | - | - | - | - | - | 326.00M | 392.60M | 475.80M | 501.10M | 510.70M | 547.30M | 585.60M | 685.00M | |||||||||
| Orkambi Growth | - | - | - | - | - | - | - | - | -36.17% | -28.27% | -18.75% | -26.85% | -33.81% | -34.82% | -33.54% | -23.21% | |||||||||
| Symdeko and Semkevi | - | - | - | - | - | - | - | - | 123.00M | 129.50M | 134.30M | 145.80M | 180.00M | 226.10M | 269.30M | 360.10M | |||||||||
| Symdeko and Semkevi Growth | - | - | - | - | - | - | - | - | -31.67% | -42.72% | -50.13% | -59.51% | -57.18% | -51.64% | -50.34% | -37.97% |
Operating Expense Breakdown
| Period Ending | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and Development | 3.91B | 3.93B | 3.83B | 3.82B | 3.63B | 3.46B | 3.39B | 3.21B | |||||||||||||||||
| Research and Development Growth | 7.69% | 13.84% | 13.05% | 19.05% | 14.78% | 13.98% | 18.24% | 19.67% | |||||||||||||||||
| Selling, General, and Administrative | 1.75B | 1.64B | 1.57B | 1.52B | 1.46B | 1.46B | 1.35B | 1.24B | |||||||||||||||||
| Selling, General, and Administrative Growth | 19.72% | 12.91% | 16.52% | 22.60% | 28.83% | 40.67% | 32.41% | 27.57% | |||||||||||||||||
| Acquired In-Process Research and Development | 133.00M | 164.00M | 124.50M | 4.57B | 4.63B | 4.56B | 4.60B | 256.80M | - | - | - | - | - | - | - | - | - | ||||||||
| Acquired In-Process Research and Development Growth | -97.13% | -96.40% | -97.29% | 1,680.14% | 778.09% | 757.06% | 802.47% | -44.25% | - | - | - | - | - | - | - | - | - | ||||||||
| Change in Value of Contingent Consideration | 2.10M | - | 2.20M | 1.80M | -500.00K | -49.60M | -48.70M | -49.80M | - | - |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.